Both Tirzepatide and this treatment represent new strategies to addressing glucose control, and increasingly, obesity. Semaglutide is a dual agonist that targets two receptors involved in glucose regulation: the incretin hormone and a similar hormone. Mounjaro, often viewed as a brand name for Ti